Cytiva at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Cytiva brings 11 presentations to ESGCT 2026 in Hamburg. Its contributions centre on making viral vectors and lipid nanoparticles at scale, from AAV purification resins and automated chromatography to stable producer cell lines. Another strand covers lipid nanoparticle platforms for engineering immune cells inside and outside the body.
| Organization | ESGCT 2026 Attendance |
|---|---|
Cytiva Marlborough, Massachusetts | |
Supplies bioprocessing equipment, consumables and cell therapy manufacturing systems used to develop and produce biologics and cell and gene therapies. | Poster Wed Oct 28 1:30pm–3:30pm A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies Poster Wed Oct 28 1:30pm–3:30pm Application-Driven Optimization of Tangential Flow Filtration for Extracellular Vesicle Manufacturing Poster Wed Oct 28 1:30pm–3:30pm Design and development of an integrated and automatic multi-step chromatography workflow for AAV purification. Poster Wed Oct 28 1:30pm–3:30pm From transient screening to stable production: a modular platform enabling accelerated, scalable and quality‑driven AAV manufacturing Poster Wed Oct 28 1:30pm–3:30pm Next-generation AAV9 affinity resin for improved yield, speed, and scalability Poster Wed Oct 28 1:30pm–3:30pm Scalable in vitro transcription using the WAVE 25 bioreactor system and Cytiva enzyme microreactor accessory Talk Thu Oct 29 1:30pm–2:30pm Solid tumors across modalities: Early decisions that shape the path to patient Cancer gene and cell therapyManufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm Accelerating Stable AAV Producer Cell Line Development Through AI-Driven Decision Intelligence Poster Thu Oct 29 2:00pm–4:00pm Redefining the Cost Equation for AAV Manufacturing: ELEVECTA™ 2.0 reshapes stable production economics Poster Thu Oct 29 2:00pm–4:00pm Synergizing Nanoplasmid vector technology and ELEVECTA™ transient cell line to improve AAV quality Poster Thu Oct 29 2:00pm–4:00pm Towards a universal lipid nanoparticle (LNP) platform for multiplex engineering of next- generation ex vivo cell therapies |
Instantly find 20 buyers from Cytiva
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction